Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $737.00

Royal Bank of Canada raised its price target for Regeneron Pharmaceuticals (REGN) to $737 from $696, maintaining a "sector perform" rating. This adjustment follows Regeneron's strong quarterly results, which saw EPS and revenue exceed analyst expectations, leading to a 3.5% increase in share price. Despite positive earnings momentum and some upward target revisions, concerns about valuation and ongoing securities litigation related to a failed melanoma trial persist among some analysts.